|
mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults
RECRUITINGPhase 1Sponsored by Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
Actively Recruiting
PhasePhase 1
SponsorVaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
Started2026-11-16
Est. completion2028-02-29
Eligibility
Age18 Years – 25 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07557602
Summary
This is a Phase 1 clinical trial to evaluate the safety and immunogenicity of VXCO-102 in healthy adult participants.
Eligibility
Age: 18 Years – 25 YearsHealthy volunteers accepted
Inclusion Criteria: * Aged 18 to 25 years, inclusive * Healthy per medical assessment based on self-reported medical history, physical examination, vital signs, and laboratory assessment Exclusion Criteria: * Self-reported or medically-documented significant medical or psychiatric condition that per medical assessment could interfere with study participation * Likely or confirmed myocarditis or pericarditis * Prior receipt of an investigational EBV vaccine * Prior receipt of a licensed vaccine within 56 days prior to Day 1 * Received more than 10 days of any systemic immunosuppressants or cytotoxic medications within 56 days prior to Day 1, any within 14 days prior to Day 1, or will need immunosuppressants at any time during the study. * For participants of childbearing potential: pregnant, breastfeeding or planning to become pregnant during the study Note: Other inclusion and exclusion criteria apply.
Conditions2
CancerEBV
Interventions1
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 1
SponsorVaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
Started2026-11-16
Est. completion2028-02-29
Eligibility
Age18 Years – 25 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07557602